WellLab®

P: +60320287551

E: welllabtests@gmail.com

WellLab URL: WellLabTests.com

26115-0013

Dr Test Doctor (Test Doctor) Test Clinic. 123 Test Street

Lab ID
Patient ID P000060
Ext ID 26115-0013

Test Patient

Sex: Female 56yrs 01-Jan-70

123 Home Street

RECEIVED
25-Apr-26

Clinical Notes .

Cardiovascular Profile Extensive

	Collected
Specimen type - Blood-Serum	15-Apr-26
Specimen type - Blood-Na Citrate	15-Apr-26
Specimen type - Blood-K2EDTA	15-Apr-26

LIPID STUDIES

TEST	RESULT	H/L	REFERENCE	UNITS
Cholesterol	5.5	H	(<5.5)	mmol/L
Triglycerides	2.2	H	(<2.0)	mmol/L
HDL (Protective)	1.1		(1.0-2.2)	mmol/L
Non-HDL Cholesterol	4.4	H	(<4.0)	mmol/L
LDL-C (Atherogenic)	3.4	H	(<3.0)	mmol/L
Cholesterol/HDLC Ratio	5.0	H	(<5.0)	ratio
LDL/HDL Ratio	2.0		(<3.2)	ratio
Trig/HDL Ratio	2.0	H	(0.5-1.7)	ratio

SPECIFIC LIPOPROTEINS

TEST	RESULT	H/L	REFERENCE	UNITS
Apolipoprotein A-1	1.41		(1.10-2.05)	g/L
Apolipoprotein B	1.13		(0.60-1.30)	g/L
Ratio (ApoB/Apo-A1)	1.13		(0.35-1.15)	ratio
Lipoprotein (a)	14.6		(<75.0)	nmol/L

CARDIOVASCULAR INFLAMMATORY MARKERS

TEST	RESULT	H/L	REFERENCE	UNITS
Glucose	8.0	H	(3.0-5.4)	mmol/L
Homocysteine	9.1		(5.0-15.0)	umol/L
High Sensitivity C-Reactive Protein	0.8		(<5.0)	mg/L
Fibrinogen	2.9		(2.0-4.5)	g/L

SAMPLE REPORT

NATA Accreditation No. 20770. The current scope of accreditation is available on the NATA website.

WellLab®

P: +60320287551

E: welllabtests@gmail.com

WellLab URL: WellLabTests.com

26115-0013

Dr Test Doctor (Test Doctor) Test Clinic. 123 Test Street

Lab ID
Patient ID P000060
Ext ID 26115-0013

Test Patient


Sex: Female 56yrs 01-Jan-70

123 Home Street

RECEIVED
25-Apr-26

LIPOSCREEN, LDL-Subfractions

TEST	RESULT	H/L	REFERENCE	UNITS
Very Low Density Lipoprotein (VLDL)	0.98	H	(<0.60)	mmol/L
Mid Density Lipoprotein (IDL-1)	0.39		(<0.60)	mmol/L
Mid Density Lipoprotein (IDL-2)	0.26		(<0.40)	mmol/L
Mid Density Lipoprotein (IDL-3)	0.31		(<0.60)	mmol/L
Low Density Lipoprotein (LDL-1)	0.88		(<1.50)	mmol/L
Low Density Lipoprotein (LDL-2)	1.06	H	(<0.80)	mmol/L
Low Density Lipoprotein (LDL-3)	0.44	H	(<0.20)	mmol/L
Low Density Lipoprotein (LDL-4)	0.03	H	(<0.01)	mmol/L
Low Density Lipoprotein (LDL-5)	0.00		(<0.01)	mmol/L
Low Density Lipoprotein (LDL-6)	0.00		(<0.01)	mmol/L
Low Density Lipoprotein (LDL-7)	0.00		(<0.01)	mmol/L
Mean Particle Size	263	L	(>268)	Angstrom
LDL Phenotype Pattern	Type B - ABNORMAL			



SAMPLE REPORT

NATA Accreditation No. 20770. The current scope of accreditation is available on the NATA website.

WellLab®
P: +60320287551
E: welllabtests@gmail.com
WellLab URL: WellLabTests.com

26115-0013

Dr Test Doctor (Test Doctor) Test Clinic. 123 Test Street

Lab ID
Patient ID P000060
Ext ID 26115-0013

Test Patient

Sex: Female 56yrs 01-Jan-70
123 Home Street

RECEIVED
25-Apr-26

Cardiovascular Profile Comment

The National Vascular Disease Prevention Alliance (NVDPA) treatment target levels for high risk people are:

Total Cholesterol <4.0 mmol/L Fasting Triglycerides < 2.0 mmol/L

Non-HDL Cholesterol <2.5 mmol/L HDL-Cholesterol >=1.00 mmol/L

LDL-Cholesterol <2.0 mmol/L

Increased non-HDL Cholesterol is a significant marker for subclinical atherosclerosis (ref: Cardiology Today 2013; 3(2): pp25-27).

LDL-C COMMENT:

Low levels of HDL cholesterol and high levels of LDL cholesterol are associated with an increased risk of atherosclerotic vascular disease. A LDL Subfractions test may be considered to determine the presence of small, dense (highly atherogenic) LDLs which are a primary cause of Coronary Artery Disease (CAD). The LDL subtypes are not detectable through conventional Lipid Profiles.

FASTING GLUCOSE HIGHLY ELEVATED:

Diagnostic of diabetes mellitus if symptomatic, OR if found on two separate occasions even without symptoms.

Fibrinogen test performed by accredited laboratory NATA: 2133

Liposcreen LDL Subfractions

The Liposcreen LDL Subfractions test provides a superior indicator for Coronary Artery Disease (CAD) risk than other conventionally available lipid profiles.

Many individuals with normal LDL and HDL cholesterol levels remain at risk from CAD, as these conventional tests do not convey the detail of the CAD risk.

Liposcreen additionally quantifies the different LDL subfractions.

LDL Phenotype Pattern:

This patient has a LDL profile Not indicative of Type A, which is deemed **ABNORMAL**.

This pattern is due to the presence of elevated levels of small dense LDLs (LDL3 – LDL7) and/or a low Mean LDL Particle Size result.

Type B (Patient may have some or all of the below present)

Deemed an ABNORMAL profile.

Predominance of small/dense (more atherogenic) LDL subclasses (LDL3, 4, 5, 6, 7).

Mean Particle Size of < 258 Angstrom (A).

Raised Cholesterol, Raised Triglycerides, Raised VLDL, Low HDLC

This profile is the designated atherogenic lipoprotein phenotype, consistent with an increased risk of CAD.

It is also characteristically prevalent in insulin-resistant states such as Metabolic Syndrome and Type 2 Diabetes mellitus.

Mean LDL Particle Size:

The LDL Mean Particle size is borderline, which may indicate the presence of LDLs of a size capable of penetrating the endothelial lining and causing the development of atheromatous plaques.

Follow up/Review Timeframe:

Follow up Liposcreen testing, for this patient, is recommended in 6 months.

SAMPLE REPORT

NATA Accreditation No. 20770. The current scope of accreditation is available on the NATA website.

WellLab®

P: +60320287551

E: welllabtests@gmail.com

WellLab URL: WellLabTests.com

26115-0013

Dr Test Doctor (Test Doctor) Test Clinic. 123 Test Street

Lab ID
Patient ID P000060
Ext ID 26115-0013

Test Patient

Sex: Female 56yrs 01-Jan-70

123 Home Street

RECEIVED
25-Apr-26

Methodology

Automated Chemistry/Immunochemistry, Gel Electrophoresis

SAMPLE REPORT

NATA Accreditation No. 20770. The current scope of accreditation is available on the NATA website.